Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system-Reference-Cited by-同舟云学术

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system

Published:2020-04 Issue:4 Volume:11 Page:829-834
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Li Yue¹,Kang Xiaohui¹^ORCID,Wang Hanping²^ORCID,Guo Xiaoxiao³^ORCID,Zhou Jiaxin⁴^ORCID,Duan Lian⁵^ORCID,Si Xiaoyan²^ORCID,Zhang Li⁶,Liu Xiaowei⁷^ORCID,Qian Jiaming¹,Zhang Li²

Affiliation:

1. Department of Gastroenterology, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

2. Department of Respiratory Medicine, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

3. Department of Cardiology, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

4. Department of Immunology, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

5. Department of Endocrinology, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

6. Department of Clinical Laboratory, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

7. Department of Ophthalmology, Peking Union Medical College HospitalChinese Academy of Medicine Sciences & Peking Union Medical College Beijing China

Funder

CAMS Innovation Fund for Medical Sciences

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13338

Reference21 articles.

1. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data

2. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma